Nintedanib ‘Superior’ to Bevacizumab for Mesothelioma Treatment

Treatment & Doctors
Reading Time: 3 mins
Publication Date: 06/11/2018
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Reviewed

Asbestos.com is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at Asbestos.com

  • Assisting mesothelioma patients and their loved ones since 2006.
  • Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed mesothelioma and support organization.
Learn More About Us

Testimonials

"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Lashawn
Mesothelioma patient’s daughter
  • Google Review Rating
  • BBB Review Rating

How to Cite Asbestos.com’s Article

APA

Povtak, T. (2022, January 12). Nintedanib ‘Superior’ to Bevacizumab for Mesothelioma Treatment. Asbestos.com. Retrieved February 6, 2023, from https://www.asbestos.com/news/2018/06/11/nintedanib-closer-approval-mesothelioma/

MLA

Povtak, Tim. "Nintedanib ‘Superior’ to Bevacizumab for Mesothelioma Treatment." Asbestos.com, 12 Jan 2022, https://www.asbestos.com/news/2018/06/11/nintedanib-closer-approval-mesothelioma/.

Chicago

Povtak, Tim. "Nintedanib ‘Superior’ to Bevacizumab for Mesothelioma Treatment." Asbestos.com. Last modified January 12, 2022. https://www.asbestos.com/news/2018/06/11/nintedanib-closer-approval-mesothelioma/.

Researchers in Austria, Germany and Hungary have added to the growing belief that the anti-cancer drug nintedanib may soon become a significant part of standard-of-care treatment for malignant pleural mesothelioma.

In their study published recently in Clinical Cancer Research, nintedanib demonstrated an ability to inhibit the growth and the migration of mesothelioma tumor cells effectively in animal models.

“This is a step in the right direction, another part of the evolutionary process of treatment advancements with this difficult disease,” Dr. Balazs Hegedus, department of thoracic surgery, University of Duisburg-Essen, told Asbestos.com. “This is an important finding.”

Nintedanib, also known by brand names Ofev and Vargetef, works by targeting a specific molecule expressed by most mesothelioma tumor cells. It functions much like bevacizumab (Avastin), one of the world’s best-selling cancer drugs, but it does so more effectively, according to this latest study.

“Importantly, this anti-tumor effect of nintedanib in experimental animals was stronger than that of bevacizumab,” Dr. Balazs Dome, head of the Translational Thoracic Oncology Program at the Medical University of Vienna in Austria said. “A key message is that nintedanib be considered superior as part of systemic anti-tumor therapy.”

Nintedanib Smothers Tumor Cells

Nintedanib inhibits tumor growth by denying cancer cells the oxygen and nutrients they need.

The drug is already approved for use with pulmonary fibrosis and certain cases of lung cancer.

There is a multicenter clinical trial, crossing several countries, already testing its effectiveness in combination with chemotherapy. It is called the LUME-Meso trial and is being watched closely.

Clinical trial sites participating within the United States include:

University of Texas MD Anderson Cancer Center, Houston

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

Greenville Health System, Greenville, S.C.

University of Alabama at Birmingham Comprehensive Cancer Center

Comprehensive Cancer Centers of Nevada, Henderson

UPMC Hillman Cancer Center

Nintedanib Gaining Momentum

The Barbara Ann Karmanos Cancer Institute in Detroit is hosting the only U.S. trial involving stand-alone treatment with nintedanib as second-line therapy for pleural mesothelioma.

The Institut Gustave Roussy in France is running a clinical trial for mesothelioma that involves nintedanib in combination with pembrolizumab (Keytruda).

The U.S. Food and Drug Administration granted nintedanib orphan drug designation in December of 2016, giving it limited availability while moving through the approval process.

“It will be exciting to see the outcome of the clinical trials,” Hegendus said. “We already know it is a safe drug and the inhibitory effect is real.”

Early LUME-Meso Results Are Impressive

Early results from the trial have been promising. They include a 9.4-month progression-free survival, which was almost double compared to chemotherapy alone.

The median overall survival benefit was 18.3 months, compared to 14.2 months for just chemotherapy.

Standard-of-care treatment for unresectable mesothelioma has been relatively ineffective for many years with a one-year survival rate hovering around 50 percent.

The regulatory industry in the United Kingdom granted early access designation earlier this year to nintedanib for use with pleural mesothelioma.

Doctors in the U.K. have been using it in combination with chemotherapy for certain lung cancers.

open book icon vector illustration
Medically Reviewed by Top Mesothelioma Doctors
Free Mesothelioma Guide